undamentalytics Newsletter
Sign in

Tscan Therapeutics, Inc. revenue

Tscan Therapeutics, Inc.'s revenue was $10.3m in fiscal 2025, up 266.7% on the year before. Since fiscal 2020 ($1.1m) it has grown at a compound 56.9% a year. Over the last twelve months it was $7.1m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue11014213107
Growth on the year before—+834.7%+33.5%+55.5%−86.6%+266.7%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Tscan Therapeutics, Inc. $7.1m 2.2% -24.3%
Evaxion A/s $7.5m 125.1% —
Roivant Sciences Ltd. $7.5m -67.6% -46.4%
HCW Biologics Inc. $6.7m 700.2% 20.4%
Adagene Inc. $7.7m 7332.8% —
Fate Therapeutics Inc $6.5m -23.4% -62.1%

Compare with peers

Head to head: EVAX vs TCRXROIV vs TCRXHCWB vs TCRXFATE vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Tscan Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tscan Therapeutics, Inc.